News Release

News Release

PARSIPPANY, N.J.--(BUSINESS WIRE)--May 19, 2015--
Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) today announced data from
three studies evaluating the clinical and pharmacoeconomic utility of
EXPAREL® (bupivacaine liposome injectable suspension) for
postsurgical pain control in patients undergoing colorectal surgery,
breast reconstruction and total knee replacement surgery. The data were
presented this month at the annual meetings of the World Congress of
Enhanced Recovery after Surgery and Perioperative Medicine, Plastic
Surgery Research Council (PSRC) and International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).

Patients who received local infiltration with EXPAREL (n=53) versus
preoperative paravertebral block (n=44) for pain control following
mastectomy with immediate tissue expander breast reconstruction
reported lower pain scores, and required less opioids and
antiemetic medication for nausea. Read the full abstract here: http://ps-rc.org/meeting/abstracts/2015/68.cgi

More patients who received EXPAREL infiltration (n=134) compared to
continuous nerve blocks via elastomeric pump (n=134) following knee
replacement surgery were able to ambulate on the day of surgery
and were discharged from the hospital in 3 days or less. Read
the full abstract here: http://www.ispor.org/RESEARCH_STUDY_DIGEST/details.asp

“This collection of data reinforces the positive impact that EXPAREL
infiltration can make on both the patient recovery experience and
hospital economics,” said Dave Stack, president, chief executive officer
and chairman of Pacira. “These studies add to the growing body of
evidence demonstrating the value of EXPAREL as part of a multimodal pain
management approach aimed at opioid minimization and enhancing patient
care.”

EXPAREL is indicated for single-dose infiltration into the surgical site
to produce postsurgical analgesia. The product combines bupivacaine with
DepoFoam®, a proven product delivery technology that delivers
medication over a desired time period. EXPAREL represents the first and
only multivesicular liposome local anesthetic that can be utilized in
the peri- or postsurgical setting. By utilizing the DepoFoam platform, a
single dose of EXPAREL delivers bupivacaine over time, providing
significant reductions in cumulative pain score with up to a 45 percent
decrease in opioid consumption; the clinical benefit of the opioid
reduction was not demonstrated. Additional information is available at www.EXPAREL.com.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.
EXPAREL has not been studied for use in patients younger than 18 years
of age. Non-bupivacaine-based local anesthetics, including lidocaine,
may cause an immediate release of bupivacaine from EXPAREL if
administered together locally. The administration of EXPAREL may follow
the administration of lidocaine after a delay of 20 minutes or more.
Other formulations of bupivacaine should not be administered within 96
hours following administration of EXPAREL. Monitoring of cardiovascular
and neurological status, as well as vital signs should be performed
during and after injection of EXPAREL as with other local anesthetic
products. Because amide-type local anesthetics, such as bupivacaine, are
metabolized by the liver, EXPAREL should be used cautiously in patients
with hepatic disease. Patients with severe hepatic disease, because of
their inability to metabolize local anesthetics normally, are at a
greater risk of developing toxic plasma concentrations. In clinical
trials, the most common adverse reactions (incidence greater-than or
equal to 10%) following EXPAREL administration were nausea,
constipation, and vomiting.

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company’s flagship product,
EXPAREL® (bupivacaine liposome injectable suspension), indicated for
single-dose infiltration into the surgical site to produce postsurgical
analgesia, was commercially launched in the United States in April 2012.
EXPAREL and two other products have successfully utilized DepoFoam®, a
unique and proprietary product delivery technology that encapsulates
drugs without altering their molecular structure, and releases them over
a desired period of time. Additional information about Pacira is
available at www.pacira.com.

Forward Looking Statements

Any statements in this press release about our future expectations,
plans, outlook and prospects, including statements about expected
non-GAAP product gross margins and operating expenses, and other
statements containing the words “believes,” “anticipates,” “plans,”
“estimates,” “expects,” and similar expressions, constitute
forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including risks relating to: the success of
our sales and manufacturing efforts in support of the commercialization
of EXPAREL; the rate and degree of market acceptance of EXPAREL; the
size and growth of the potential markets for EXPAREL and our ability to
serve those markets; our plans to expand the use of EXPAREL to
additional indications, including nerve block, oral surgery and chronic
pain, as well as pediatrics; the related timing and success of a United
States Food and Drug Administration supplemental New Drug Application;
our receipt of FDA approval of our nerve block indication; the adverse
effects and impacts of FDA warning letters; the outcome of the U.S.
Department of Justice inquiry; our plans to evaluate, develop and pursue
additional DepoFoam-based product candidates; clinical studies in
support of an existing or potential DepoFoam-based product; our plans to
continue to manufacture and provide support services for our commercial
partners who have licensed DepoCyt(e); our commercialization and
marketing capabilities; our and Patheon UK Limited’s ability to
successfully and timely construct dedicated EXPAREL manufacturing
suites; and other factors discussed in the “Risk Factors” of our most
recent Annual Report on Form 10-K for the fiscal year ended December 31,
2014, and in other filings that we periodically make with the SEC. In
addition, the forward-looking statements included in this press release
represent our views as of the date of this press release. Important
factors could cause our actual results to differ materially from those
indicated or implied by forward-looking statements, and as such we
anticipate that subsequent events and developments will cause our views
to change. However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim any
obligation to do so. These forward-looking statements should not be
relied upon as representing our views as of any date subsequent to the
date of this press release.

Shareholder Tools

EXPAREL, the EXPAREL logo, iovera⁰, the iovera⁰ logo, Pacira, and the Pacira logo are registered trademarks of Pacira BioSciences, Inc. All other trademarks referenced herein are the property of their respective owners.